Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialize M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
GSK and Merck KGaA, Darmstadt, Germany today announced that they have entered into a global strategic alliance
-
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GSK announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company
-
GSK announces succession plan to appoint new Chairman
GSK announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman
-
Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine
GSK today announced the publication of positive results from two phase III studies of single-dose tafenoquine
-
GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture
GSK has reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture.
-
GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
-
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
-
GSK employees celebrate Giving Tuesday with awards to local nonprofits
GSK employees celebrate Giving Tuesday with awards to local nonprofits
-
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval
-
Access to Medicine Index 2018 media statement
Access to Medicine Index 2018 media statement
-
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma (1)
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
-
GSK awards Greater Philadelphia nonprofits making a dynamic IMPACT on health outcomes
GSK awards Greater Philadelphia nonprofits making a dynamic IMPACT on health outcomes
-
GSK announces $1 million grant to protect children in North Carolina, Puerto Rico from disaster
GSK announces $1 million grant to protect children in North Carolina, Puerto Rico from disaster
-
GSK awards Triangle nonprofits making a dynamic IMPACT on health outcomes
Ten nonprofits will receive $40,000 to support life coaching, mentorship, healthy eating, literacy, and other social determinants of health.
-
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation.
-
GSK delivers Q3 sales of £8.1 billion, +3% AER, +6% CER
Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER
-
GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Marked patient benefit observed in phase II study supports further clinical development of GSK3196165 for RA.
-
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
-
Positive results from Harmony Outcomes study of albiglutide published in The Lancet (1)
GSK and the Duke Clinical Research Institute (DCRI) today announced publication of positive results from the Harmony Outcomes study.
-
GSK ships 2018-19 seasonal influenza vaccines for US market
GSK will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2018-19 flu season.
